基于Markov模型的利培酮与阿立哌唑治疗精神分裂症的药物经济学评价OA

Objective To evaluate the long-term economic benefits of risperidone and aripiprazole in the treatment of schizophrenia using markov model.Methods Based on the published data of clinical randomized controlled trials on risperidone and aripiprazole in the treatment of schizophrenia,a Markov model of the treatment of schizophrenia with two drugs was constructed and the parameters of the model were set.The health outcomes and resource consumption of the two drugs for schizophrenia were compared,and cost-effectiveness and sensitivity analyses were performed.Results Markov simulated risperidone and aripiprazole to treat schizophrenia for 3 years,with an average cost of $14396 and $16147,respectively,and gained 14.03 and 13.77 quality-adjusted life years(QALYs),respectively.The risperidone treatment regimen cost $1751 less for each additional QALY received.When the drug price drops by 10%or 20%,there is no effect on the result,and risperidone is still the preferred solution.Conclusion Compared with aripiprazole,the risperidone treatment regimen offers greater cost savings and is a superior regimen for the clinical treatment of schizophrenia.